DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Major Shareholder Buys $3,000,000.00 in Stock

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) major shareholder Koch Thomas Von bought 1,200,000 shares of the stock in a transaction on Friday, June 28th. The shares were bought at an average price of $2.50 per share, for a total transaction of $3,000,000.00. Following the purchase, the insider now directly owns 5,526,435 shares in the company, valued at approximately $13,816,087.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

DiaMedica Therapeutics Price Performance

Shares of NASDAQ DMAC remained flat at $2.95 during midday trading on Monday. 236,702 shares of the stock traded hands, compared to its average volume of 48,892. DiaMedica Therapeutics Inc. has a 12-month low of $1.94 and a 12-month high of $4.45. The stock has a market capitalization of $111.99 million, a PE ratio of -4.82 and a beta of 1.74. The company has a 50-day moving average price of $2.77 and a two-hundred day moving average price of $2.82.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its earnings results on Wednesday, May 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.02. On average, analysts predict that DiaMedica Therapeutics Inc. will post -0.67 EPS for the current year.

Institutional Investors Weigh In On DiaMedica Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Avantax Advisory Services Inc. purchased a new stake in DiaMedica Therapeutics in the 4th quarter worth approximately $36,000. Stonebridge Capital Advisors LLC bought a new position in DiaMedica Therapeutics in the 3rd quarter worth approximately $52,000. Paragon Associates & Paragon Associates II Joint Venture boosted its stake in DiaMedica Therapeutics by 6.4% in the 4th quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company’s stock worth $1,420,000 after purchasing an additional 30,000 shares during the period. Finally, Vanguard Group Inc. boosted its stake in DiaMedica Therapeutics by 26.3% in the 1st quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company’s stock worth $2,807,000 after purchasing an additional 211,351 shares during the period. 10.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on DMAC. Oppenheimer reaffirmed an “outperform” rating and set a $6.00 price target (down previously from $7.00) on shares of DiaMedica Therapeutics in a research report on Thursday, March 21st. Craig Hallum began coverage on shares of DiaMedica Therapeutics in a research report on Wednesday, April 24th. They set a “buy” rating and a $8.00 price target for the company.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.